Category: 19989-66-3

On July 7, 2011, Su, Wei-Guo; Jia, Hong; Dai, Guangxiu published a patent.Application of 19989-66-3 The title of the patent was Preparation of triazolopyrazine derivatives and analogs for use as c-MET kinase activity inhibitors. And the patent contained the following:

Title compounds I [X = N or CR6; Y = absent, O, S, or NR7; R1 = (un)substituted fused bicyclic heteroaryl, when X is CR6 and Y is absent; or (un)substituted aryl or heteroaryl, when X is N and Y is o, S, or NR7; or (un)substituted heteroaryl, when X is CR6 and Y is O, S, or NR7; R2 and R3 independently = H, or alkyl; or together with the C atom to which they are attached form a cycloalkyl or heterocyclyl; R4 = halo, (un)substituted alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; R6 = H, OH, NH2, halo, etc.; R5 = H, halo, OH NH2, CF3, etc.; R7 = H or alkyl; with provisions], and their pharmaceutically acceptable salts, are prepared and disclosed as c-MET kinase activity inhibitors. Thus, e.g., II was prepared by a multistep procedure (preparation given). Select I were evaluated in c-MET kinase activity inhibition assays (using transcreener FP) (data given). The experimental process involved the reaction of Benzo[d]thiazol-6-ylmethanol(cas: 19989-66-3).Application of 19989-66-3

The Article related to pyrazine triazolo derivative preparation cmet kinase activity inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Application of 19989-66-3

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On February 23, 2006, Blake, James F.; Fell, Jay Bradford; Fischer, John P.; Hendricks, Robert Than; Robinson, John E.; Spencer, Stacey Renee; Stengel, Peter J. published a patent.Recommanded Product: Benzo[d]thiazol-6-ylmethanol The title of the patent was Preparation of benzothiazine dioxides as antivirals.. And the patent contained the following:

Title compounds [I; R1 = OH, halo, NO2, cyano, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, (substituted) Ph, phenylalkyl, PhO, etc.; R6 = H, alkyl; A = specified hydroxyquinolone, hydroxypyrazolone, hydroxypyrrolone, hydroxypyridone, etc. residues], were prepared as hepatitis C virus NS5B RNA polymerase inhibitors (no data). Thus, title compound (II) was prepared in 5 steps from 2-aminothiophenol, Et 4-chloroacetoacetate, and 1-isoamylisatoic anhydride. The experimental process involved the reaction of Benzo[d]thiazol-6-ylmethanol(cas: 19989-66-3).Recommanded Product: Benzo[d]thiazol-6-ylmethanol

The Article related to benzothiazine dioxide preparation antiviral, hcv infection treatment benzothiazine dioxide preparation, hepatitis c virus polymerase inhibitor benzothiazine dioxide preparation and other aspects.Recommanded Product: Benzo[d]thiazol-6-ylmethanol

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On June 18, 2009, Ellman, Jonathan A.; Brak, Katrien published a patent.Related Products of 19989-66-3 The title of the patent was Triazole derivatives and aminocoumarin derivatives as nonpeptidic inhibitors of cruzain and their preparation and use in the treatment of Chagas disease. And the patent contained the following:

Cruzain is the major cysteine protease of T. cruzi, which is the causative agent of Chagas’ disease and is a promising target for the development of chemotherapy. With the goal of developing potent nonpeptidic inhibitors of cruzain, of formula I, the substrate activity screening method was used to screen a library of protease substrates initially designed to target the homologous human protease cathepsin S. Structure-based design was next used to further improve substrate cleavage efficiency by introducing addnl. binding interactions in the S3 pocket of cruzain. Substrates of formula I wherein R1 is H, OH and derivatives, NH2 and derivatives, SH and derivatives, SOH and derivatives, SO2H and derivatives, SO2NH2 and derivatives, NO2, halo, CN, (un)substituted (hetero)alkyl, etc.; are claimed. The optimized substrates were then converted to inhibitors by the introduction of cysteine protease mechanism-based pharmacophores. Inhibitors II and III were prepared by multistep procedures (procedures given). Inhibitor II was determined to be reversible even though it incorporated the vinyl sulfone pharmacophore that is well documented to give irreversible cruzain inhibition for peptidic inhibitors. The previously unexplored β-chloro vinyl sulfone pharmacophore provided mechanistic insight that led to the development of potent irreversible acyl- and aryl- oxymethyl ketone cruzain inhibitors. For these inhibitors, potency did not solely depend on leaving group pTa, with 2,3,5,6-tetrafluorophenoxy Me ketone III identified as one of the most potent inhibitors with a second order inactivation constant of 147,000 s-1M-1. This inhibitor completely eradicated the T. cruzi parasite from mammalian cell cultures and consequently has the potential to lead to new chemo therapeutics for Chagas’ disease. The experimental process involved the reaction of Benzo[d]thiazol-6-ylmethanol(cas: 19989-66-3).Related Products of 19989-66-3

The Article related to triazole derivative preparation nonpeptidic cruzain inhibitor treatment chagas disease, aminocoumarin derivative preparation nonpeptidic cruzain inhibitor treatment chagas disease and other aspects.Related Products of 19989-66-3

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Jagadeesh, Rajenahally V.; Junge, Henrik; Beller, Matthias published an article in 2014, the title of the article was Green synthesis of nitriles using non-noble metal oxides-based nanocatalysts.Application In Synthesis of Benzo[d]thiazol-6-ylmethanol And the article contains the following content:

An environmentally benign chemoselective synthesis of structurally diverse aryl, heterocyclic, allylic and aliphatic nitriles from easily available alcs. applying aqueous ammonia and mol. oxygen was described. Key to success for this synthesis was the use of nitrogen-doped graphene-layered non-noble metal oxides as stable and durable nanocatalysts. As an example a renewable synthesis of adiponitrile, an industrially important bulk chem. was reported. The experimental process involved the reaction of Benzo[d]thiazol-6-ylmethanol(cas: 19989-66-3).Application In Synthesis of Benzo[d]thiazol-6-ylmethanol

The Article related to aryl heterocyclic allylic aliphatic nitrile chemoselective green preparation, alc ammonia oxygen ammoxidation metal oxide nanocatalyst, metal oxide nitrogen doped graphene layer nanocatalyst preparation and other aspects.Application In Synthesis of Benzo[d]thiazol-6-ylmethanol

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On October 3, 2013, Saito, Noriko; Egi, Jun; Nagai, Hiroshi; Ueno, Megumi; Shintani, Yusuke; Inaba, Yusuke; Adachi, Michiaki; Hirai, Yuichi; Kawazu, Takeshi; Yasutake, Koichi; Takahashi, Daiki published a patent.Recommanded Product: 19989-66-3 The title of the patent was Preparation of triazinone compounds as T-type calcium channel inhibitors. And the patent contained the following:

The title compounds [I; R1 = H, halo, each (un)substituted C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, mono- or di(C1-6 alkyl)amino, or C3-11 cycloalkyl; L1, L2 = a single bond, (un)substituted NH or C1-6 alkylene, O, S(O), SO2; B = each (un)substituted C3-11 cycloalkylene, C3-11 cycloalkenylene, 3-11 membered heterocyclylene, C6-14 arylene, 5-10 membered heteroarylene, C1-6 alkylene, C2-6 alkenylene, or C2-6 alkynylene; A = each (un)substituted C1-6 alkyl, C2-6 alkenyl, C3-11 cycloalkyl, C3-11 cycloalkenyl, 3-11 membered heterocyclyl, C6-14 aryl, or 5-10 membered heteroaryl; L3 = (un)substituted C1-6 alkylene optionally having one of the methylene groups replaced by C(O) or C(S); D = each (un)substituted C3-11 cycloalkyl, C3-11 cycloalkenyl, 3-11 membered heterocyclyl, C6-14 aryl, or 5-10 membered heteroaryl], tautomers or pharmaceutically acceptable salts of the compounds, or solvates of the compounds, the tautomers or the pharmaceutically acceptable salts are prepared These compounds have an inhibitory activity on a T-type voltage-dependent calcium channel and are useful for the prevention, treatment, and/or improvement of diseases for which the T-type calcium channel-inhibitory activity are effective, in particular pain, more specifically neuropathic pain. Thus, amination of 1,3,5-trichlorotriazine with 1-(4-fluorophenyl)piperazine dihydrochloride in the presence of Na2CO3 in THF at room temperature for 3 days quant. gave 2,4-dichloro-6-[4-(4-fluorophenyl)piperazin-1-yl]-1,3,5-triazine which underwent hydrolysis with aqueous NaOH solution at room temperature for 2 days and 2 h to give 79% 6-chloro-4-[4-(4-fluorophenyl)piperazin-1-yl]-1,3,5-triazin-2(1H)-one (II; X = Cl). Hydrogenation of II (X = Cl) in the presence of Pd(OH)2/activated charcoal in aqueous acetic acid solution under hydrogen atm. at room temperature for 3 days gave 99% 4-[4-(4-fluorophenyl)piperazin-1-yl]-1,3,5-triazin-2(1H)-one II (X = H) which underwent benzylation by 4-chlorobenzyl bromide in the presence of K2CO3 in N,N-dimethylformamide at 70° for 5 h to give 53% 1-(4-Chlorobenzyl)-4-[4-(4-fluorophenyl)piperazin-1-yl]-1,3,5-triazin-2(1H)-one (III). III and (R)-4-[4-(4-fluorophenyl)-5-hydroxy-5,6-dihydropyridin-1(2H)-yl]-1-[[5-(trifluoromethyl)thiophen-2-yl]methyl]-1,3,5-triazin-2(1H)-one (IV) showed IC50 of 0.17 and 0.00046 μM, resp., for inhibiting the cellular calcium influx in KSE293 cells expressing human type T calcium channel (Cav3.2). The experimental process involved the reaction of Benzo[d]thiazol-6-ylmethanol(cas: 19989-66-3).Recommanded Product: 19989-66-3

The Article related to triazinone preparation t type calcium channel inhibitor, benzylphenylpiperazinyltriazinone phenylpyridinylthiophenylmethyltriazinone preparation t type calcium channel inhibitor, pain neuropathic pain treatment prevention improvement triazinone preparation and other aspects.Recommanded Product: 19989-66-3

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On January 5, 2012, Uchida, Hiroshi; Asagarasu, Akira; Matsui, Teruaki published a patent.SDS of cas: 19989-66-3 The title of the patent was Preparation of heterocyclic carbamate and carboxylic acid hydrazide compounds as p27Kip1 degradation inhibitors. And the patent contained the following:

There are provided novel heterocyclic compounds and salts thereof applicable in the selective inhibition of the degradation of cyclin-dependent kinase inhibitor protein (p27Kip1) for the prevention and/or treatment of cell proliferative diseases such as cancer, rheumatism, diabetes, obesity, endometriosis, prostatic hypertrophy (prostatic hyperplasia), and inflammation. The title compounds and salts thereof represented in formula [I; A represents an alkyl group, a cycloalkyl group, an aryl group, or a heterocyclic group, and group A can have a substituent group; ring B represents a 5- to 8- membered monocyclic heterocyclic ring or a condensed ring containing this monocyclic heterocyclic ring, and ring B can have a substituent group; ring C represents an aromatic ring, and ring C can have a substituent group; L represents a linker having 3-5 atoms in the main chain selected from carbon atoms, nitrogen atoms, oxygen atoms, and sulfur atoms, and having at least one heteroatom selected from nitrogen atoms, oxygen atoms, and sulfur atoms, and linker L can have a substituent group; and n represents 0 or 1.] are prepared Thus, 1.11 g 2-(4-chloro-2-methoxyphenyl)-4-methylthiazole-5-carboxylic acid and 870 mg (1,2,3,4-Tetrahydrobenzo[d]pyrido[2,1-b]imidazol-7-yl)methanol were suspended in 50 mL toluene, successively treated with 475 mg Et3N and 1.18 g diphenylphosphoryl azide, and refluxed for 2 h to give, after workup and silica gel chromatog., 71% [2-(4-chloro-2-methoxyphenyl)-4-methylthiazol-5-yl]carbamic acid 1,2,3,4-tetrahydrobenzo[d]pyrido[2,1-b]imidazol-7-ylmethyl ester (II). II and 3-pyrazolylmethyl 5-benzimidazolylcarbamate derivative (III) in vitro induced apoptosis of human prostatic cancer cells (PC-3 cells) at 0.025 and 0.00625 μM, resp., and in vitro showed IC50 of 6.70 and 0.43 nM, resp., against PC-3 cells. The experimental process involved the reaction of Benzo[d]thiazol-6-ylmethanol(cas: 19989-66-3).SDS of cas: 19989-66-3

The Article related to p27kip1 degradation inhibitor heterocyclic carbamate preparation, heterocyclic carboxylic acid hydrazide preparation, cyclin dependent kinase inhibitor protein p27kip1 degradation inhibitor, cell proliferative disease prevention treatment, cancer rheumatism diabetes obesity endometriosis prevention treatment and other aspects.SDS of cas: 19989-66-3

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On August 16, 2001, Fotouhi, Nader; Gillespie, Paul; Guthrie, Robert William; Pietranico-Cole, Sherrie Lynn; Yun, Weiya published a patent.Synthetic Route of 19989-66-3 The title of the patent was Preparation of N-aroyldehydroamino acids as lymphocyte function associated antigen-1 antagonists.. And the patent contained the following:

Title compounds [I; R1 = H, OH, amino, halo; R2 = H, OH, halo; R3 = H; R2R3 = atoms to form Ph, pyrrole, pyrroline, pyrazole, triazole, imidazole, etc., rings; A = CH2CH2CH(OH), CH2CH2CO, CH2NHCO, etc.; R4, R5 = H, Me, Et; B = H, alkyl, (substituted) (bicyclic) (hetero)aryl, etc.; R6 = CO2H, CO2R7, CH2OH, etc.; R7 = alkyl, dimethylaminoalkyl, pyrrolidinylalkyl, etc.], were prepared Thus, Me (Z)-3-(1H-benzotriazol-5-yl)-2-[[2-chloro-4-[[(3-hydroxybenzyl)amino]carbonyl]-6-methylbenzoyl]amino]propenoate (preparation given) was stirred 125 h with LiOH in MeOH/THF/H2O to give 61% (Z)-3-(1H-benzotriazol-5-yl)-2-[[2-chloro-4-[[(3-hydroxybenzyl)amino]carbonyl]-6-methylbenzoyl]amino]propenoic acid. The latter inhibited LFA-1 binding to immobilized ICAM-1 with IC50 = 0.4 nM. The experimental process involved the reaction of Benzo[d]thiazol-6-ylmethanol(cas: 19989-66-3).Synthetic Route of 19989-66-3

The Article related to aroyldehydroamino acid preparation lymphocyte function associated antigen antagonist, propenoate aroylamino preparation lfa1 antagonist, amino acid dehydro aroyl lymphocyte function associated antigen antagonist, t cell activation inhibitor aroylaminopropenoate preparation, psoriasis graft rejection dermatitis asthma arthritis treatment aroylaminopropenoate and other aspects.Synthetic Route of 19989-66-3

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica